Loading..

AVEO Pharmaceuticals, Inc. (AVEO) Report Analysis

Corporate Events

Negative

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropp...

2022-06-24 00:00:00

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from Russell Microcap Value Index

Neutral

Aveo Pharmaceuticals, Inc. Announces Clinical T...

2022-06-22 12:00:00

AVEO Pharmaceuticals, Inc. announced that it has entered into a clinical trial collaboration and supply agreement in North America with Eli Li...

Positive

AVEO Oncology Announces Updated National Compre...

2022-06-21 12:00:00

AVEO Oncology announced the National Comprehensive Cancer Network has elevated FOTIVDA® (tivozanib) to Category 1 status as a subsequent thera...

Neutral

AVEO Pharmaceuticals, Inc. Presents at 5th LSX ...

2022-06-16 19:39:00

AVEO Pharmaceuticals, Inc. Presents at 5th LSX USA Congress & CEO Forums, Jun-22-2022 09:15 AM. Venue: Boston, United States. Speakers: Michae...

Neutral

AVEO Pharmaceuticals, Inc. Presents at H.C. Wai...

2022-05-18 12:30:00

AVEO Pharmaceuticals, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-25-2022 01:30 PM. Venue: Fontainebleau Miami Bea...

Neutral

AVEO Pharmaceuticals, Inc. Reaffirms Earnings G...

2022-05-05 11:22:00

AVEO Pharmaceuticals, Inc. reaffirmed earnings guidance for the full year 2022. The company expects net product revenues between $100.0 millio...

Neutral

AVEO Pharmaceuticals, Inc. to Report Q1, 2022 R...

2022-04-28 12:30:00

AVEO Pharmaceuticals, Inc. announced that they will report Q1, 2022 results on May 05, 2022

Neutral

AVEO Pharmaceuticals, Inc., Q1 2022 Earnings Ca...

2022-04-28 12:30:00

AVEO Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 05, 2022

Neutral

AVEO Pharmaceuticals, Inc., Annual General Meet...

2022-04-26 21:14:00

AVEO Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2022, at 10:00 Eastern Standard Time. Location: donnelley financial solutions, 20 ...

Neutral

AVEO Pharmaceuticals, Inc. Proposes Amendment t...

2022-04-26 21:14:00

AVEO Pharmaceuticals, Inc. at the Annual Meeting of Stockholders to be held on June 7, 2022, proposed to approve an amendment to the Restated ...

Positive

AVEO Pharmaceuticals, Inc. Enter into an Office...

2022-04-08 20:18:00

On April 4, 2022, AVEO Pharmaceuticals, Inc. (Company) entered into an office lease agreement (the “Office Lease”) with TFC 30 Winter, LLC (th...

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Glo...

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami B...

Positive

Aveo Oncology Highlights Recent Progress and 20...

2022-01-04 13:05:00

AVEO Oncology highlighted its recent progress and outlook for 2022. The team executed the U.S. commercial build out by hiring and training fie...

Neutral

AVEO Oncology Announces Clinical Trial Collabor...

2022-01-04 13:00:00

AVEO Oncology announced that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany to ev...

Neutral

AVEO Pharmaceuticals, Inc. Presents at LifeSci ...

2021-12-16 17:17:00

AVEO Pharmaceuticals, Inc. Presents at LifeSci Partners 11th Annual Corporate Access Event (virtual), Jan-05-2022 .

Negative

AVEO Oncology Appoints Jeb Ledell as Chief Oper...

2021-12-01 12:00:00

AVEO Oncology announced the appointment of Jeb Ledell as chief operating officer. In this role, he will be responsible for overseeing operatio...

Neutral

LifeSci Partners, LifeSci Partners 11th Annual ...

2021-11-20 00:00:00

LifeSci Partners, LifeSci Partners 11th Annual Corporate Access Event (virtual), Jan 05, 2022 through Jan 07, 2022.

Neutral

AVEO Pharmaceuticals, Inc. Presents at Stifel 2...

2021-11-11 00:30:00

AVEO Pharmaceuticals, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-15-2021 01:20 PM. Venue: New York, New York, United States.

Neutral

AVEO Pharmaceuticals, Inc. Presents at 4th Annu...

2021-11-11 00:29:00

AVEO Pharmaceuticals, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 12:35 PM.

Neutral

AVEO Pharmaceuticals, Inc. to Report Q3, 2021 R...

2021-11-01 11:00:00

AVEO Pharmaceuticals, Inc. announced that they will report Q3, 2021 results on Nov 08, 2021

Neutral

AVEO Pharmaceuticals, Inc., Q3 2021 Earnings Ca...

2021-11-01 11:00:00

AVEO Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 08, 2021

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global...

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, Unit...

Positive

AVEO Oncology Announces Ficlatuzumab Grants Fas...

2021-09-20 11:00:00

AVEO Oncology announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ficlatuzumab for the trea...

Positive

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) added...

2021-09-20 00:00:00

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) added to S&P Global BMI Index

Neutral

LSX Ltd, 5th LSX USA Congress & CEO Forums, Jun...

2021-09-04 07:34:00

LSX Ltd, 5th LSX USA Congress & CEO Forums, Jun 21, 2022 through Jun 22, 2022. Venue: Boston, United States.

Neutral

AVEO Pharmaceuticals, Inc. Presents at H.C. Wai...

2021-08-31 01:02:00

AVEO Pharmaceuticals, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York P...

Negative

AVEO Pharmaceuticals, Inc. Announces Retirement...

2021-08-27 21:02:00

On August 27, 2021, AVEO Pharmaceuticals, Inc. announced that Michael Needle, M.D., Chief Medical Officer of the Company, will retire from emp...

Neutral

AVEO Pharmaceuticals, Inc. Presents at Baird Gl...

2021-08-26 17:20:00

AVEO Pharmaceuticals, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 03:10 PM. Speakers: Michael P. Bailey, CEO, Presid...

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCO...

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Neutral

Robert W. Baird & Co. Incorporated, Baird Globa...

2021-08-10 13:03:00

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.

Neutral

AVEO Pharmaceuticals, Inc., Q2 2021 Earnings Ca...

2021-07-29 11:00:00

AVEO Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 05, 2021

Neutral

AVEO Pharmaceuticals, Inc. to Report Q2, 2021 R...

2021-07-29 11:00:00

AVEO Pharmaceuticals, Inc. announced that they will report Q2, 2021 results on Aug 05, 2021

Neutral

AVEO Pharmaceuticals, Inc. - Special Call

2021-07-08 20:05:00

To discuss on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma

Neutral

Stifel, Nicolaus & Company, Incorporated, Stife...

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New ...

Negative

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from Russell Microcap Value Index

2022-06-24 00:00:00

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from Russell Microcap Value Index

Neutral

Aveo Pharmaceuticals, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for Erbitux® (Cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic Hnscc

2022-06-22 12:00:00

AVEO Pharmaceuticals, Inc. announced that it has entered into a clinical trial collaboration and supply agreement in North America with Eli Lilly and Company (Lilly) to evaluate ficlatuzumab in combination with ERBITUX® (cetuximab), an anti-EGFR antibody, in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ficlatuzumab is AVEO’s investigational potent humanized immunoglobulin G1 monoclonal antibody that targets hepatocyte growth factor. Under the terms of the agreement, Lilly will provide cetuximab clinical drug supply in the U.S. and Canada for AVEO’s potential registrational study, which will assess ficlatuzumab with cetuximab in HPV negative R/M HNSCC. AVEO will serve as the study sponsor and will be responsible for trial execution. In June 2021, AVEO announced positive results from a randomized Phase 2 study of ficlatuzumab alone or in combination with cetuximab in patients with pan-refractory metastatic HNSCC. Of note, patients with HPV negative disease, a subgroup normally associated with poorer outcomes, who received the ficlatuzumab and cetuximab combination demonstrated both a superior overall response rate, including two patients with complete responses, and median progression free survival superior to historical data for current standards of care. In September 2021, the FDA awarded Fast Track designation for the combination of ficlatuzumab and cetuximab in HPV negative relapsed/recurrent HNSCC.

Positive

AVEO Oncology Announces Updated National Comprehensive Cancer Network Clinical Practice Guidelines Elevate Fotivda (Tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced Renal Cell Carcinoma Patients

2022-06-21 12:00:00

AVEO Oncology announced the National Comprehensive Cancer Network has elevated FOTIVDA® (tivozanib) to Category 1 status as a subsequent therapy for RCC patients who have received two or more prior therapies in the latest Kidney Cancer Treatment Guidelines released on June 17, 2022. The NCCN Clinical Practice Guidelines are the recognized standard for clinical policy in cancer care and are developed through review of evidence and recommendations from physicians and oncology researchers. The current NCCN RCC guidelines make treatment recommendations for first-line or subsequent therapy options for RCC patients and are referenced in the development of other clinical pathways.

Neutral

AVEO Pharmaceuticals, Inc. Presents at 5th LSX USA Congress & CEO Forums, Jun-22-2022 09:15 AM

2022-06-16 19:39:00

AVEO Pharmaceuticals, Inc. Presents at 5th LSX USA Congress & CEO Forums, Jun-22-2022 09:15 AM. Venue: Boston, United States. Speakers: Michael P. Bailey, CEO, President & Director.

Neutral

AVEO Pharmaceuticals, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-25-2022 01:30 PM

2022-05-18 12:30:00

AVEO Pharmaceuticals, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-25-2022 01:30 PM. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.

Neutral

AVEO Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full Year 2022

2022-05-05 11:22:00

AVEO Pharmaceuticals, Inc. reaffirmed earnings guidance for the full year 2022. The company expects net product revenues between $100.0 million and $110.0 million.

Neutral

AVEO Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022

2022-04-28 12:30:00

AVEO Pharmaceuticals, Inc. announced that they will report Q1, 2022 results on May 05, 2022

Neutral

AVEO Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 05, 2022

2022-04-28 12:30:00

AVEO Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 05, 2022

Neutral

AVEO Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2022

2022-04-26 21:14:00

AVEO Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2022, at 10:00 Eastern Standard Time. Location: donnelley financial solutions, 20 custom house street, 7th floor, Boston Massachusetts United States Agenda: To consider and approve an amendment to restated certificate of incorporation to increase the number of authorized shares of common stock from 50,000,000 to 80,000,000; approve an amendment to the aveo pharmaceuticals, inc. 2019 equity incentive plan to increase the number of shares of common stock reserved for issuance thereunder; and to discuss other matters.

Neutral

AVEO Pharmaceuticals, Inc. Proposes Amendment to Restated Certificate of Incorporation

2022-04-26 21:14:00

AVEO Pharmaceuticals, Inc. at the Annual Meeting of Stockholders to be held on June 7, 2022, proposed to approve an amendment to the Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 to 80,000,000.

Positive

AVEO Pharmaceuticals, Inc. Enter into an Office Lease Agreement with TFC 30 Winter, LLC

2022-04-08 20:18:00

On April 4, 2022, AVEO Pharmaceuticals, Inc. (Company) entered into an office lease agreement (the “Office Lease”) with TFC 30 Winter, LLC (the “Landlord”) to lease 6,465 square feet of office space located at 30 Winter Street, Boston, Massachusetts 02108 (the “Premises”). The purpose of the Office Lease is to allow the Company to continue leasing the Company’s current office space following the expiration of the Company’s current lease agreement for an additional two years beginning on November 30, 2022 (the "commencement date") and ending on November 29, 2024 (the "expiration date"). The Company has the ability to extend the term of the Office Lease for three additional years following the expiration date. Under the terms of the Office Lease, starting on the commencement date, the Company will lease the Premises for $26,937.50 per month in base rent for the first twelve months and $27,476.25 per month for the remaining twelve months until the expiration date, each exclusive of operating expenses and taxes.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.

Positive

Aveo Oncology Highlights Recent Progress and 2022 Outlook

2022-01-04 13:05:00

AVEO Oncology highlighted its recent progress and outlook for 2022. The team executed the U.S. commercial build out by hiring and training field teams and building infrastructure – including distribution, patient access and securing broad reimbursement. Market penetration for FOTIVDA has continued to increase since its commercial launch at the end of March 2021. Feedback from the field team suggests FOTIVDA has been well received by oncologists treating r/r RCC, noting both the durable responses and tolerability profile they have observed as attractive for their third-line patients. As with other launches during the COVID-19 pandemic, the sales team’s access to oncologists and their staff has been limited which the Company believes has potentially slowed the launch trajectory. This headwind continued in the fourth quarter of 2021 with the emergence of the Delta and Omicron COVID-19 variants. Despite these access challenges, AVEO expects to have continued quarter over quarter net revenue and underlying prescription demand growth in the fourth quarter of 2021. In addition, as is typical with launches in the relapsed/refractory oncology setting, physicians will tend to prescribe newly approved therapies for later line patients and, following positive experience with a new therapy, will prescribe to earlier line patients. To date, the majority of the patients prescribed FOTIVDA have been 4th line or later. Expect later line patients to generally exhibit higher early discontinuation rates. With slower account access due to COVID-19 related restrictions, the Company believes that broad product adoption in earlier lines of treatment may continue to be protracted. AVEO continues to believe FOTIVDA has the potential to become a standard of care for patients that have received two or more prior systemic treatments. These data included updated durability of response (DOR) and overall survival (OS) results, as well as an analysis of treatment-emergent adverse events (TEAEs) across trial arms. Tivozanib demonstrated clinically meaningful and statistically significant improvements in overall response rate (ORR) and DOR compared to sorafenib in highly relapsed or refractory RCC patients in the TIVO-3 trial. In addition, the long-term OS relative to sorafenib continued to improve with a hazard ratio of 0.91, as presented at ASCO 2021. Patients in the TIVO-3 trial demonstrated a longer duration of treatment exposure with tivozanib than sorafenib (11.9 cycles vs. 6.7 cycles), but fewer all-grade and grade =3 TEAEs. The observed TEAEs were generally similar with tivozanib and sorafenib. Patients receiving tivozanib in the TIVO-3 trial required fewer dose reductions, and the time to dose reductions were longer with tivozanib than sorafenib. Data highlighting outcomes of the subgroup of TIVO-3 patients who received tivozanib following prior axitinib therapy suggests that tivozanib, a potent and selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), is more active following prior VEGFR TKI therapy than sorafenib, a multi-targeted VEGFR TKI. Tivozanib demonstrated significantly increased quality-adjusted time without symptoms of disease and toxicity (QTWiST) relative to sorafenib as third- or fourth-line therapy in patients with RCC. A Phase 3 clinical trial of tivozanib in combination with Bristol-Myers Squibb’s OPDIVO® (nivolumab), an antibody directed against programmed death-1 (PD-1), versus tivozanib monotherapy for the treatment of RCC patients progressing after one or two ines of prior therapy, one of which must include immunotherapy, opened for enrollment during the third quarter of 2021. This is a study of tivozanib in combination with IMFINZI® (durvalumab), AstraZeneca’s human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in patients with unresectable locally advanced or metastatic HCC. The trial has completed enrollment of the first-line cohort and is currently enrolling a second cohort of patients after pre-treatment with bevacizumab and atezolizumab in a prior line of therapy. The Company expects to present the data from the first-line cohort at ASCO GI in January 2022. Data from the portion of the trial that included patients with HPV negative disease, a subgroup of metastatic HNSCC normally associated with poorer outcomes, who received the combination of ficlatuzumab and cetuximab demonstrated improved responses, including two patients with complete responses, which compares favorably to historical controls. BAVEO has begun the manufacturing scale up and expects to commence manufacturing of ficlatuzumab clinical supply in the second quarter of 2022. In support of the proposed HPV negative HNSCC Phase 3 clinical trial of ERBITUX® (cetuximab) and ficlatuzumab, AVEO recently entered into a clinical trial collaboration and supply agreement for ERBITUX for the EU study sites with Merck KGaA, Darmstadt, Germany. AVEO expects to continue to discuss potential ficlatuzumab registrational clinical trial designs with the FDA and with potential partners. AV-380 is a first-in-class, potent, humanized inhibitory IgG1 monoclonal antibody targeting growth differentiation factor 15 (GDF15), a potential treatment pathway for cancer and/or cachexia. The last patient has been dosed in the Phase 1 clinical trial of AV-380 in healthy volunteers. AVEO expects to present data from the Phase 1 clinical trial in mid-2022 at a scientific meeting. AVEO plans to initiate a Phase 1b clinical trial in cancer patients in mid-2022. During 2021, AVEO regained worldwide rights to AV-203. AV-203 is a clinical-stage potent humanized IgG1 monoclonal antibody that targets ErbB3 (also known as HER3). AV-203 has demonstrated preclinical activity in a number of different tumor models, including breast, head and neck, lung, ovarian and pancreatic cancers. FOTIVDA® (tivozanib) is an oral, next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability. AVEO received U.S. Food and Drug Administration (FDA) approval for FOTIVDA on March 10, 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

Neutral

AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA

2022-01-04 13:00:00

AVEO Oncology announced that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany to evaluate ficlatuzumab in combination with ERBITUX® (cetuximab), an EGFR-targeted antibody, in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ficlatuzumab is AVEO’s investigational potent humanized immunoglobulin G1 monoclonal antibody that targets hepatocyte growth factor. Under the terms of the agreement, Merck KGaA, Darmstadt, Germany will provide cetuximab clinical drug supply in all countries outside of the U.S. and Canada for AVEO’s future registrational study, which will assess ficlatuzumab with cetuximab in HPV negative R/M HNSCC. AVEO will serve as the study sponsor and will be responsible for costs associated with the trial execution. The Company expects to commence manufacturing of ficlatuzumab clinical supply in the second quarter of 2022, subject to availability of key raw materials and manufacturing supplies also used in COVID-19 vaccine manufacturing, with the initiation of a registrational study now anticipated in the first half of 2023. The Company expects to continue to discuss potential ficlatuzumab pivotal study designs with the FDA and to continue ongoing partnership dialogues.

Neutral

AVEO Pharmaceuticals, Inc. Presents at LifeSci Partners 11th Annual Corporate Access Event (virtual), Jan-05-2022

2021-12-16 17:17:00

AVEO Pharmaceuticals, Inc. Presents at LifeSci Partners 11th Annual Corporate Access Event (virtual), Jan-05-2022 .

Negative

AVEO Oncology Appoints Jeb Ledell as Chief Operating Officer

2021-12-01 12:00:00

AVEO Oncology announced the appointment of Jeb Ledell as chief operating officer. In this role, he will be responsible for overseeing operational functions key to maximizing the Company’s organizational efficiency and advancing its pipeline of products.

Neutral

LifeSci Partners, LifeSci Partners 11th Annual Corporate Access Event (virtual), Jan 05, 2022 through Jan 07, 2022

2021-11-20 00:00:00

LifeSci Partners, LifeSci Partners 11th Annual Corporate Access Event (virtual), Jan 05, 2022 through Jan 07, 2022.

Neutral

AVEO Pharmaceuticals, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-15-2021 01:20 PM

2021-11-11 00:30:00

AVEO Pharmaceuticals, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-15-2021 01:20 PM. Venue: New York, New York, United States.

Neutral

AVEO Pharmaceuticals, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 12:35 PM

2021-11-11 00:29:00

AVEO Pharmaceuticals, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 12:35 PM.

Neutral

AVEO Pharmaceuticals, Inc. to Report Q3, 2021 Results on Nov 08, 2021

2021-11-01 11:00:00

AVEO Pharmaceuticals, Inc. announced that they will report Q3, 2021 results on Nov 08, 2021

Neutral

AVEO Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 08, 2021

2021-11-01 11:00:00

AVEO Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 08, 2021

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Positive

AVEO Oncology Announces Ficlatuzumab Grants Fast Track Designation by the U.S. FDA

2021-09-20 11:00:00

AVEO Oncology announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma (R/R HNSCC). Ficlatuzumab is AVEO’s investigational potent humanized immunoglobulin G1 monoclonal antibody that targets hepatocyte growth factor.

Positive

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) added to S&P Global BMI Index

2021-09-20 00:00:00

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) added to S&P Global BMI Index

Neutral

LSX Ltd, 5th LSX USA Congress & CEO Forums, Jun 21, 2022 through Jun 22, 2022

2021-09-04 07:34:00

LSX Ltd, 5th LSX USA Congress & CEO Forums, Jun 21, 2022 through Jun 22, 2022. Venue: Boston, United States.

Neutral

AVEO Pharmaceuticals, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM

2021-08-31 01:02:00

AVEO Pharmaceuticals, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States.

Negative

AVEO Pharmaceuticals, Inc. Announces Retirement of Michael Needle as Chief Medical Officer, with Effect from November 19, 2021

2021-08-27 21:02:00

On August 27, 2021, AVEO Pharmaceuticals, Inc. announced that Michael Needle, M.D., Chief Medical Officer of the Company, will retire from employment with the Company effective as of November 19, 2021 (such date, the “Effective Date”). Dr. Needle will remain the Chief Medical Officer through the Effective Date.

Neutral

AVEO Pharmaceuticals, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 03:10 PM

2021-08-26 17:20:00

AVEO Pharmaceuticals, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 03:10 PM. Speakers: Michael P. Bailey, CEO, President & Director.

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Neutral

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021

2021-08-10 13:03:00

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.

Neutral

AVEO Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 05, 2021

2021-07-29 11:00:00

AVEO Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 05, 2021

Neutral

AVEO Pharmaceuticals, Inc. to Report Q2, 2021 Results on Aug 05, 2021

2021-07-29 11:00:00

AVEO Pharmaceuticals, Inc. announced that they will report Q2, 2021 results on Aug 05, 2021

Neutral

AVEO Pharmaceuticals, Inc. - Special Call

2021-07-08 20:05:00

To discuss on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma

Neutral

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New York, United States.

Fundamental Summary

According to their recent financial report, which was published on 2022-05-05, AVEO Pharmaceuticals had several impressive financial metrics that should make them more attractive than their peers going forward. Their positive growth and income factors indicate that AVEO Pharmaceuticals is likely to continue to produce impressive results for the foreseeable future, as well. There should be significant upside potential for the stock looking forward. We gave AVEO Pharmaceuticals a 78 rating and a HOLD recommendation.

AVEO Pharmaceuticals reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 20.92 million compared to USD 1.92 million a year ago. Net loss was USD 10.2 million compared to USD 22.12 million a year ago. Basic loss per share from continuing operations was USD 0.3 compared to USD 0.81 a year ago.

Business Description

AVEO Pharmaceuticals, a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company’s preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent’s Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals in March 2005. AVEO Pharmaceuticals was incorporated in 2001 and is headquartered in Boston, Massachusetts.

Sector Overview

AVEO Pharmaceuticals is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. AVEO Pharmaceuticals's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 98.2 -6.8% 68
Liabilities 61.3 3.0% 76
Price to Book 3.8 6.4% 60
Cash & Equivalents 73.8 4.7% 78
Equity 36.9 -19.5% 61
EBITDA -38.8 20.7% 89
Total Revenues 61.3 44.9% 38
Parameter Value Change Score
Return on Equity -75.7 42.4% 54
Net Cashflow -47.6 -641.7% 94
Capital Expenditure -0.1 0.0% 74
Asset Turnover 0.5 10.6% 83
Free Cashflow -1.4 21.9% 87

* All values are TTM

The below chart reflects AVEO Pharmaceuticals's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While AVEO Pharmaceuticals's peer average final assessment score stands on 66.0, AVEO Pharmaceuticals's score is 78.

  •  AVEO
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 0 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 1 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 2 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 3 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 4 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 6 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 7 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 8 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 9 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 10 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 11 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 12 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 13 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 14 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 15 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 16 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 17 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 18 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 20 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 21 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 22 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 24 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 25 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 26 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 27 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 28 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 29 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 30 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 31 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 32 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 33 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 34 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 35 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 36 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 37 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 39 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 40 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 41 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 42 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 43 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 44 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 45 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 47 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 48 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 50 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 51 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 54 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 55 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 56 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 57 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 58 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 59 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 60 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 61 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 62 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 63 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 64 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 65 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 66 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 68 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 69 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 70 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 73 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 74 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 75 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 76 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 77 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 80 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 81 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 82 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 83 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 84 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 86 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 87 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 88 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 89 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 90 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 91 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 92 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 93 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. AVEO Pharmaceuticals's stock is now priced above its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the near, medium, and long-term. In particular, many institutional investors keep close watch of the 200-day moving average. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), AVEO Pharmaceuticals's stock indicates that it's likely oversold. Overall, these technical indicators signal positive upward momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 78.

Bullish 78
Close Price 6.4
52W Low 3.15
52W High 7.4
5D MA 6.17
50D MA 4.6
200D MA 5.16
MACD 0.5
RSI 11.9
STOCH 89.93

Balance Sheet Analysis

Cash & Equivalents and Liabilities stood out as the most significant drivers of AVEO Pharmaceuticals's balance sheet strength. AVEO Pharmaceuticals reported a positive trendline in their cash and cash equivalents metrics. Specifically, they reported that cash and cash equivalents were 73.8, representing 4.7% change from the last report. Its impressive cash and cash equivalents metrics should support upward pressure on its's stock price. Consequently, their cash and cash equivalents movement received a grade of 78. Also, AVEO Pharmaceuticals is doing a good job of keeping its liabilities under control and growing intelligently. At filing, their liabilities were 61.3, representing 3.0% change from the previous period. This performance is all interesting relative to their peers and suggests that their stock price has room to grow to reflect a higher intrinsic value. Therefore, we rated their liabilities movement with a score of 76. However, one concerning metric, Book Value Factors, stood out. AVEO Pharmaceuticals's price to book ratio (P/B) was reported as 3.8 and represents 6.4% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. They does not yet appear to be headed in the right direction to achieve strong book value metrics. Disappointing results in book value factors typically precede negative pressure in stock prices, so its book value factors received a grade of 60. Therefore, their balance sheet earned a grade of 66.

Parameter Value Change Score
Assets 98.2 -6.8% 68
Liabilities 61.3 3.0% 76
Price to Book 3.8 6.4% 60
Cash & Equivalents 73.8 4.7% 78
Equity 36.9 -19.5% 61
* All values are TTM

The below chart describes AVEO Pharmaceuticals's performance as reflected on its balance sheet with respect to its peers. While AVEO Pharmaceuticals received a balance sheet score of 66, the average of its peers stands on 65.0.

  •  AVEO
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 0 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 1 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 2 1
Vericel Corporation 1.1B 51 65 56 53 61 57 3 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 4 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 6 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 7 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 8 1
Immatics N.V. 538.7M 56 70 84 95 73 76 9 1
Agenus Inc. 520.5M 73 62 37 55 60 54 10 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 11 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 12 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 13 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 14 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 15 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 16 1
Amgen Inc. 130.1B 72 68 86 53 62 69 17 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 18 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 20 1
BioNTech SE 34.0B 75 69 64 97 73 75 21 1
Seagen Inc. 32.9B 59 68 55 43 66 61 22 1
Biogen Inc. 29.7B 57 72 92 50 76 76 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 24 1
Incyte Corporation 16.8B 71 72 95 82 79 83 25 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 26 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 27 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 28 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 29 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 30 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 31 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 32 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 33 1
Alkermes plc 5.0B 63 66 46 54 71 62 34 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 35 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 36 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 37 1
Natera, Inc. 3.6B 73 65 43 95 42 54 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 39 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 40 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 41 1
CureVac N.V. 2.6B 49 64 75 52 52 57 42 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 43 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 44 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 45 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 47 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 48 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 50 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 51 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 54 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 55 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 56 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 57 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 58 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 59 1
CareDx, Inc 1.2B 54 67 52 39 51 52 60 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 61 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 62 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 63 1
MannKind Corporation 957.2M 79 59 50 40 64 57 64 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 65 1
Merus N.V. 941.6M 59 68 50 83 81 70 66 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 68 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 69 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 70 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 73 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 74 1
Geron Corporation 566.2M 69 72 37 59 62 60 75 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 76 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 77 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
Affimed N.V. 415.0M 56 66 63 56 47 54 80 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 81 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 82 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 83 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 84 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 86 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 87 1
AC Immune SA 299.8M 84 64 47 53 75 68 88 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 89 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 90 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 91 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 92 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 93 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Overall, AVEO Pharmaceuticals's critical income statement metrics appear to strongly support positive growth going forward. AVEO Pharmaceuticals reported impressive EBITDA this period. At filing, EBITDA was reported as -38.8, representing 20.7% change from the previous period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. The company is headed in the right direction regarding EBITDA, exhibiting efficient capital controls and strong overall financial performance. The company's EBITDA movement, therefore, received a grade of 89. Also, Return factors metrics and ratios were exceptional in this report. AVEO Pharmaceuticals reported a return on equity (ROE) ratio of -75.7, representing a change of 42.4% from the last report. The company appears headed in the right direction in terms of these return factors, exhibiting prudent capital expenditure growth compared to its peers. Therefore, its return factors component earned a score of 54. On the other hand, Revenue Efficiency, jumped out as looking rather underwhelming. AVEO Pharmaceuticals reported discouraging numbers for its revenue efficiency. As of the current filing, they were reported as 61.3 and represented 44.9% change from the previous period. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency does not make a compelling case for upward pressure on the company's stock price. Its revenue efficiency, therefore, received a grade of 38. Therefore, their income statement earned a grade of 74.

Parameter Value Change Score
EBITDA -38.8 20.7% 89
Total Revenues 61.3 44.9% 38
Return on Equity -75.7 42.4% 54
* All values are TTM

The below chart describes AVEO Pharmaceuticals's performance as reflected on its income statement with respect to its peers. While AVEO Pharmaceuticals received a income statement score of 74 , the average of its peers stands on 68.0.

  •  AVEO
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Exact Sciences Corporation 7.2B 57 67 54 62 0 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 1 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 2 1
Vericel Corporation 1.1B 76 44 82 56 3 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 4 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 6 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 7 1
CTI BioPharma Corp. 603.6M 84 50 62 59 8 1
Immatics N.V. 538.7M 37 93 53 77 9 1
Agenus Inc. 520.5M 57 83 45 74 10 1
Vaxart, Inc. 440.0M 99 51 72 68 11 1
MiMedx Group, Inc. 391.5M 87 43 83 59 12 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 13 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 14 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 15 1
DermTech, Inc. 165.3M 49 48 78 52 16 1
Amgen Inc. 130.1B 74 75 64 78 17 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 18 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 20 1
BioNTech SE 34.0B 41 89 75 79 21 1
Seagen Inc. 32.9B 54 65 70 62 22 1
Biogen Inc. 29.7B 90 57 73 70 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 24 1
Incyte Corporation 16.8B 59 77 60 73 25 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 26 1
United Therapeutics Corporation 10.6B 57 91 54 82 27 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 28 1
Exelixis, Inc. 6.7B 54 91 54 81 29 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 30 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 31 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 32 1
Ascendis Pharma A/S 5.2B 38 68 46 54 33 1
Alkermes plc 5.0B 69 55 81 62 34 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 35 1
Novavax, Inc. 4.0B 41 89 54 75 36 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 37 1
Natera, Inc. 3.6B 52 51 78 52 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 39 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 40 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 41 1
CureVac N.V. 2.6B 45 83 71 74 42 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 43 1
Insmed Incorporated 2.4B 51 58 73 57 44 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 45 1
Abgenix Inc. 2.1B 47 47 47 47 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 47 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 48 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 50 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 51 1
Xencor, Inc. 1.6B 42 94 52 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 54 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 55 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 56 1
Veracyte, Inc. 1.4B 45 63 57 55 57 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 58 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 59 1
CareDx, Inc 1.2B 61 44 82 50 60 1
IVERIC bio, Inc. 1.1B 84 58 79 70 61 1
FibroGen, Inc. 1.0B 48 74 63 67 62 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 63 1
MannKind Corporation 957.2M 95 48 56 61 64 1
ImmunoGen, Inc. 946.1M 40 73 71 64 65 1
Merus N.V. 941.6M 48 60 59 54 66 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 68 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 69 1
Amarin Corporation plc 734.5M 95 44 82 63 70 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 73 1
AnaptysBio, Inc. 586.3M 97 50 77 68 74 1
Geron Corporation 566.2M 89 67 73 78 75 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 76 1
Radius Health, Inc. 499.8M 94 71 68 82 77 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
Affimed N.V. 415.0M 95 49 75 66 80 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 81 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 82 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 83 1
Zymeworks Inc. 324.7M 58 53 77 56 84 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 86 1
Silence Therapeutics plc 313.4M 83 64 69 72 87 1
AC Immune SA 299.8M 83 61 65 70 88 1
Precigen, Inc. 299.1M 57 87 59 79 89 1
bluebird bio, Inc. 288.7M 99 91 61 96 90 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 91 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 92 1
MacroGenics, Inc. 184.6M 95 56 74 71 93 1
Chimerix, Inc. 178.4M 99 50 62 65 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Overall, AVEO Pharmaceuticals's critical cash flow metrics appear to signal strong support and a high likelihood of positive growth going forward. AVEO Pharmaceuticals's management was effective in improving their net cash flow, which now sits at -47.6 and represents a -641.7% change from the previous report. The company is headed in the right direction regarding business priorities, exhibiting prudent net cash flow management and growth. Consequently, their net cash flow movement received a grade of 94. Also, AVEO Pharmaceuticals's published free cash flow numbers were substantial and reflected management's focus on a healthy change strategy. AVEO Pharmaceuticals recorded free cash flow of -1.4, which represents a 21.9% change from the previous report. This parameter coud affect companies in the same industry and market capitalization by up to 2.6%. These free cash flow numbers show that management has executed well while generating cash flow and encouraging growth. The company's free cash flow movement, therefore, received a grade of 87. That said, one metric, Capital Expenditure, stood out as particularly concerning. AVEO Pharmaceuticals's management was ineffective in materially improving CapEx, which now sits at -0.1 and represents a 0.0% change from the previous report. This performance is all the more uninspiring relative to their peers and competitors. Consequently, their CapEx movement received a grade of 74. Their cash flow received an overall score of 95.

Parameter Value Change Score
Net Cashflow -47.6 -641.7% 94
Capital Expenditure -0.1 0.0% 74
Asset Turnover 0.5 10.6% 83
Free Cashflow -1.4 21.9% 87
* All values are TTM

The below chart describes AVEO Pharmaceuticals's performance as reflected on its cash flow with respect to its peers. While AVEO Pharmaceuticals received a cash flow score of 95, the average of its peers stands on 70.0.

  •  AVEO
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Exact Sciences Corporation 7.2B 53 45 80 46 56 0 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 1 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 2 1
Vericel Corporation 1.1B 64 46 59 73 65 3 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 4 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 6 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 7 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 8 1
Immatics N.V. 538.7M 82 95 56 99 86 9 1
Agenus Inc. 520.5M 57 43 52 77 58 10 1
Vaxart, Inc. 440.0M 72 56 53 38 65 11 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 12 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 13 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 14 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 15 1
DermTech, Inc. 165.3M 60 51 45 86 58 16 1
Amgen Inc. 130.1B 80 74 67 74 81 17 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 18 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 20 1
BioNTech SE 34.0B 73 97 50 52 72 21 1
Seagen Inc. 32.9B 53 53 50 87 58 22 1
Biogen Inc. 29.7B 58 54 90 73 66 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 24 1
Incyte Corporation 16.8B 78 79 92 74 84 25 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 26 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 27 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 28 1
Exelixis, Inc. 6.7B 79 90 89 83 87 29 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 30 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 31 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 32 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 33 1
Alkermes plc 5.0B 89 95 76 80 92 34 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 35 1
Novavax, Inc. 4.0B 62 38 63 54 60 36 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 37 1
Natera, Inc. 3.6B 52 54 56 84 58 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 39 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 40 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 41 1
CureVac N.V. 2.6B 87 80 90 70 90 42 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 43 1
Insmed Incorporated 2.4B 79 80 61 89 82 44 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 45 1
Abgenix Inc. 2.1B 66 53 45 59 58 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 47 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 48 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 50 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 51 1
Xencor, Inc. 1.6B 96 95 70 95 98 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 54 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 55 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 56 1
Veracyte, Inc. 1.4B 90 95 46 46 82 57 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 58 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 59 1
CareDx, Inc 1.2B 98 84 40 50 86 60 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 61 1
FibroGen, Inc. 1.0B 86 74 48 87 84 62 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 63 1
MannKind Corporation 957.2M 77 56 43 37 66 64 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 65 1
Merus N.V. 941.6M 70 71 74 53 71 66 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 68 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 69 1
Amarin Corporation plc 734.5M 52 40 74 55 55 70 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 73 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 74 1
Geron Corporation 566.2M 78 68 49 81 77 75 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 76 1
Radius Health, Inc. 499.8M 64 40 37 56 57 77 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
Affimed N.V. 415.0M 72 57 95 43 74 80 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 81 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 82 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 83 1
Zymeworks Inc. 324.7M 52 65 45 83 57 84 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 86 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 87 1
AC Immune SA 299.8M 66 77 79 63 68 88 1
Precigen, Inc. 299.1M 82 75 37 85 74 89 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 90 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 91 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 92 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 93 1
Chimerix, Inc. 178.4M 80 84 95 47 83 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.